Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their bladder drug vinflunine. The therapy had been a key part of BMS's strategy for a comeback in cancer therapies. Feedback from the FDA prompted the reversal. BMS is expected to seek approval soon for the melanoma drug ipilimumab, which is being developed in partnership with Medarex.
- here's the report [1]
- and here's an article [2] from Scientific American on BMS' cancer efforts
Links:
[1] http://money.cnn.com/news/newsfeeds/articles/djf500/200710251027DOWJONESDJONLINE000865_FORTUNE5.htm
[2] http://www.sciam.com/article.cfm?alias=bristol-breast-cancer-dru&chanId=sa003&modsrc=reuters